Heart surgery patients get new hope: colchicine may stop Post-Op AFib

NCT ID NCT06798714

Recruiting now Disease control Sponsor: Tomsk Cardiology Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether the anti-inflammatory drug colchicine, combined with a special surgical technique, can prevent atrial fibrillation (a type of irregular heartbeat) after coronary artery bypass surgery. Researchers will compare 70 patients receiving colchicine plus the new technique against 70 patients getting standard care. The goal is to reduce dangerous heart-rhythm problems after surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: colchicine
What this could lead to: If it works, this could offer a simple, low-cost way to prevent a common heart-rhythm problem after bypass surgery.
What could go wrong: This is a small, early-phase trial with only 140 people, so results may not apply to everyone. Colchicine can cause stomach upset or other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colchicine poisoning coronary artery disorder atrial fibrillation prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL FIBRILLATION COLCHICINE CORONARY ARTERY BYPASS GRAFTING CORONARY ARTERY DISEASE

Contacts and locations

Locations

Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia
RECRUITING

Tomsk, 634012, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.